DEVELOPMENT OF OUTPATIENT ANTIVIRAL COCKTAILS AGAINST SARS-COV-2 AND OTHER POTENTIAL PANDEMIC RNA VIRUSES. - ABSTRACT: THE OVERALL PLATFORM AND OBJECTIVE OF THE STANFORD AVIDD CENTER, “SYNERX,” IS TO DEVELOP OUTPATIENT ANTIVIRAL COCKTAILS AGAINST SARS-COV-2 AND OTHER POTENTIAL PANDEMIC RNA VIRUSES. THUS, THE GOAL OF EACH OF OUR 7 PROJECTS IS TO DEVELOP TOWARDS THE CLINIC A NOVEL DIRECT-ACTING ANTIVIRAL (DAA) WITH A DISTINCT MECHANISM OF ACTION, SO THAT THEY CAN BE USED ALONE AND IN COMBINATION WITH OTHER AGENTS—PROVIDING ADDITIVE, AND IDEALLY SYNERGISTIC ANTIVIRAL ACTIVITY. TO MAXIMIZE THE ACHIEVEMENT OF THIS GOAL, WE SEEK TO CREATE 3 SCIENTIFIC CORES THAT WILL EACH PROVIDE CRITICAL EXPERTISE AND RESOURCES: THE STRUCTURAL BIOLOGY CORE TO OFFER CRITICAL INSIGHTS INTO OUR PROJECTS’ ANTIVIRAL TARGETS AND MECHANISMS OF ACTION; THE PANDEMIC ASSISTANCE CORE TO ENSURE ADEQUATE ACCESS TO FACILITIES WITH THE REQUISITE BIOSAFETY AND CONTAINMENT TO SAFELY DEVELOP OUR PROJECTS’ ANTIVIRALS AGAINST

Summary

DEVELOPMENT OF OUTPATIENT ANTIVIRAL COCKTAILS AGAINST SARS-COV-2 AND OTHER POTENTIAL PANDEMIC RNA VIRUSES. - ABSTRACT: THE OVERALL PLATFORM AND OBJECTIVE OF THE STANFORD AVIDD CENTER, “SYNERX,” IS TO DEVELOP OUTPATIENT ANTIVIRAL COCKTAILS AGAINST SARS-COV-2 AND OTHER POTENTIAL PANDEMIC RNA VIRUSES. THUS, THE GOAL OF EACH OF OUR 7 PROJECTS IS TO DEVELOP TOWARDS THE CLINIC A NOVEL DIRECT-ACTING ANTIVIRAL (DAA) WITH A DISTINCT MECHANISM OF ACTION, SO THAT THEY CAN BE USED ALONE AND IN COMBINATION WITH OTHER AGENTS—PROVIDING ADDITIVE, AND IDEALLY SYNERGISTIC ANTIVIRAL ACTIVITY. TO MAXIMIZE THE ACHIEVEMENT OF THIS GOAL, WE SEEK TO CREATE 3 SCIENTIFIC CORES THAT WILL EACH PROVIDE CRITICAL EXPERTISE AND RESOURCES: THE STRUCTURAL BIOLOGY CORE TO OFFER CRITICAL INSIGHTS INTO OUR PROJECTS’ ANTIVIRAL TARGETS AND MECHANISMS OF ACTION; THE PANDEMIC ASSISTANCE CORE TO ENSURE ADEQUATE ACCESS TO FACILITIES WITH THE REQUISITE BIOSAFETY AND CONTAINMENT TO SAFELY DEVELOP OUR PROJECTS’ ANTIVIRALS AGAINST